Latha Vairavan's most recent trade in Arcutis Biotherapeutics Inc was a trade of 435 Common Stock done at an average price of $21.1 . Disclosure was reported to the exchange on May 11, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics Inc | Latha Vairavan | SVP Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.05 per share. | 11 May 2026 | 435 | 85,978 (0%) | 0% | 21.1 | 9,157 | Common Stock |
| Arcutis Biotherapeutics Inc | Latha Vairavan | SVP Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 23.61 per share. | 04 May 2026 | 1,341 | 86,413 (0%) | 0% | 23.6 | 31,662 | Common Stock |
| Arcutis Biotherapeutics Inc | Latha Vairavan | SVP Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2026 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Latha Vairavan | SVP Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2026 | 27,000 | 90,607 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Latha Vairavan | SVP Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 25.16 per share. | 27 Feb 2026 | 2,772 | 87,835 (0%) | 0% | 25.2 | 69,745 | Common Stock |
| Arcutis Biotherapeutics Inc | Latha Vairavan | SVP Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 25.91 per share. | 27 Feb 2026 | 81 | 87,754 (0%) | 0% | 25.9 | 2,099 | Common Stock |
| Arcutis Biotherapeutics Inc | Latha Vairavan | SVP Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 25.50 per share. | 02 Feb 2026 | 1,320 | 63,607 (0%) | 0% | 25.5 | 33,658 | Common Stock |
| Arcutis Biotherapeutics Inc | Latha Vairavan | SVP Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 24.72 per share. | 03 Nov 2025 | 88 | 64,927 (0%) | 0% | 24.7 | 2,175 | Common Stock |
| Arcutis Biotherapeutics Inc | Latha Vairavan | SVP Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.33 per share. | 04 Aug 2025 | 89 | 65,015 (0%) | 0% | 14.3 | 1,275 | Common Stock |
| Arcutis Biotherapeutics Inc | Latha Vairavan | SVP Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2025 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Latha Vairavan | SVP Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2025 | 20,000 | 65,104 (0%) | 0% | 0 | Common Stock |